| 标题 |
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial |
| 网址 | |
| DOI |
10.1016/S2468-1253(25)00296-1
doi
|
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |